EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues
ARS Pharmaceuticals, Inc. (SPRY) had EBITDA Margin of -217.86% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$84.28M |
|
$-171.39M |
|
$20.42M |
|
$63.85M |
|
$263.73M |
|
$-179.45M |
|
$8.07M |
|
$-171.38M |
|
$-171.38M |
|
$-171.30M |
|
$-171.30M |
|
$-171.30M |
|
$-171.30M |
|
$-179.45M |
|
$-183.60M |
|
98.57M |
|
98.57M |
|
$-1.74 |
|
$-1.74 |
|
| Balance Sheet Financials | |
$284.90M |
|
$2.46M |
|
$42.76M |
|
$327.65M |
|
$39.15M |
|
$168.51M |
|
$174.25M |
|
$213.39M |
|
$114.26M |
|
$99.81M |
|
$114.26M |
|
99.29M |
|
| Cash Flow Statement Financials | |
$-170.87M |
|
$56.77M |
|
$104.60M |
|
$50.82M |
|
$41.32M |
|
$-9.50M |
|
$22.09M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.28 |
|
-- |
|
-- |
|
0.60 |
|
1.47 |
|
75.77% |
|
-212.92% |
|
-212.92% |
|
|
EBITDA Margin |
-217.86% |
-203.35% |
|
-203.37% |
|
$-171.21M |
|
-- |
|
-- |
|
-- |
|
0.26 |
|
2.44 |
|
3.33 |
|
109.78 |
|
-149.92% |
|
-171.63% |
|
-52.28% |
|
-60.58% |
|
$1.15 |
|
$-1.74 |
|
$-1.73 |
|